A Phase III Randomized Double-blind Placebo-controlled Multicenter Basket Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Satralizumab in Patients with Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) or Anti-Leucine-rich-glioma-inactivated 1 (LGI-1) Encephalitis

Brief description of study

The purpose of this study is to assess the effects, good or bad, of satralizumab in patients with autoimmune encephalitis.

Satralizumab is an experimental drug, which means the United States Food and Drug Administration (FDA) has not approved satralizumab for the treatment of autoimmune encephalitis. Satralizumab has been approved for treatment of another immune disease of the nervous system, called "neuro-myelitis optica spectrum disease", which causes inflammation of the eye nerves and spinal cord.

Clinical Study Identifier: s23-00375
ClinicalTrials.gov Identifier: NCT05503264
Principal Investigator: Claude Steriade.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.